Cardlytics, Inc. (NASDAQ:CDLX) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in Cardlytics, Inc. (NASDAQ:CDLX) by 223.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 58,026 shares of the company’s stock after acquiring an additional 40,112 shares during the quarter. Barclays PLC owned approximately 0.11% of Cardlytics worth $186,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its stake in shares of Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares in the last quarter. Renaissance Technologies LLC increased its stake in Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after buying an additional 307,800 shares in the last quarter. RBF Capital LLC raised its holdings in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after acquiring an additional 369,620 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Cardlytics in the third quarter valued at approximately $45,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cardlytics in the third quarter worth approximately $153,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on CDLX. Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective for the company. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.92.

Cardlytics Stock Down 8.4 %

NASDAQ CDLX opened at $3.49 on Tuesday. The business’s fifty day simple moving average is $3.91 and its 200-day simple moving average is $4.81. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm has a market cap of $177.37 million, a PE ratio of -0.57 and a beta of 1.53. Cardlytics, Inc. has a 52 week low of $2.89 and a 52 week high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same period in the previous year, the firm earned ($0.26) earnings per share. Cardlytics’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, equities analysts anticipate that Cardlytics, Inc. will post -1.52 earnings per share for the current year.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,007 shares of company stock worth $251,297. Insiders own 4.40% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.